A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ADNP / activity-dependent neuroprotective protein

[Related PubMed/MEDLINE]
Total Number of Papers: 139
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ADNP  (>> Co-occurring Abbreviation)
Long Form:   activity-dependent neuroprotective protein
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Activity-Dependent Neuroprotective Protein (ADNP)-Derived Peptide (NAP) Counteracts UV-B Radiation-Induced ROS Formation in Corneal Epithelium. PACAP, UVB
2022 All in the Family: Living With ADNP Syndrome. ---
2022 DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. AD, aDS, DS
2022 Proximity labeling identifies a repertoire of site-specific R-loop modulators. ---
2022 SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism. ELM, MT, SH3, SHANK3
2022 The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease. BDNF, CNS, D3R, PACAP, PD, VIP
2021 Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. aMCI, EBs, MTs, NAP, PSP, Tau3R, Tau4R
2021 ADNP prompts the cisplatin-resistance of bladder cancer via TGF-beta-mediated epithelial-mesenchymal transition (EMT) pathway. BC, CCK-8, EMT, IHC, qRT-PCR
2021 Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. AD, MAPRE1, SIRT1
10  2021 PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy. PACAP
11  2021 Sensory Reactivity Symptoms Are a Core Feature of ADNP Syndrome Irrespective of Autism Diagnosis. ASD
12  2021 Utilizing an Animal Model to Identify Brain Neurodegeneration-Related Biomarkers in Aging. GNMT, GNMT-KO, GnRH, SAMe
13  2021 Zinc Binding to NAP-Type Neuroprotective Peptides: Nuclear Magnetic Resonance Studies and Molecular Modeling. AD, MALDI ToF, MS, NMR
14  2020 ADNP Controls Gene Expression Through Local Chromatin Architecture by Association With BRG1 and CHD4. PrE
15  2020 ADNP promotes neural differentiation by modulating Wnt/beta-catenin signaling. ---
16  2020 ADNP Upregulation Promotes Bladder Cancer Cell Proliferation via the AKT Pathway. BC, CCK-8, qRT-PCR
17  2020 Age and Sex-Dependent ADNP Regulation of Muscle Gene Expression Is Correlated with Motor Behavior: Possible Feedback Mechanism with PACAP. FOXP2, GC, MYL, PACAP
18  2020 Episignatures Stratifying Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype. HVDAS
19  2020 Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond. Bac, Bif, Coer, MIB
20  2020 Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain. FoxP2, VIP, ZF
21  2020 Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting. male
22  2020 Tauopathy in the young autistic brain: novel biomarker and therapeutic target. ASD, ID, MAPT
23  2020 The ADNP Syndrome and CP201 (NAP) Potential and Hope. ---
24  2020 VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects. D-SKIP, EB, MWM, PACAP, VIP
25  2019 A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP. ADNF, EBs
26  2019 ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging. CDC5L
27  2019 Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain. ABR, ASD
28  2019 Direct evidence for binding of aluminum to NAP anti-amyloid peptide and its analogs. FTIR, MS
29  2019 Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study. AD, ID, MT
30  2019 NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. MT
31  2019 Neuroprotective Peptide NAPVSIPQ Antagonizes Ethanol Inhibition of L1 Adhesion by Promoting the Dissociation of L1 and Ankyrin-G. NAP
32  2019 The autism-mutated ADNP plays a key role in stress response. PACAP, VIP
33  2019 The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse. DTI, VGLUT1
34  2018 Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice. ---
35  2018 Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. ---
36  2018 Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes. ---
37  2018 NAP Protects against Tau Hyperphosphorylation Through GSK3. AD, GSK-3beta, NFT
38  2017 ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease. AD, ASD
39  2017 ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. EB, MAPs, MAPs, MT
40  2017 Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats. AD, LTP, MWM, PPF
41  2017 Interaction between FMDV Lpro and transcription factor ADNP is required for optimal viral replication. FMDV, IFN, Lpro
42  2017 NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. BRB, DME
43  2017 Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children. ASD, RNA-Seq
44  2017 Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress. AD, RGS2
45  2017 The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings. ---
46  2016 Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. PD
47  2016 D-SAL and NAP: Two Peptides Sharing a SIP Domain. ADNF, D-SAL, EBs, NAP
48  2016 Impairment of mitochondria dynamics by human A53T alpha-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. ---
49  2016 Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats. GABA, GAD, GFAP, Glu, HPLC, VIP
50  2016 Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease. MCI
51  2016 Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. ASD, BECN1, EBs
52  2015 Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies. AD, ASD, eIF4E
53  2015 Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer's disease. ---
54  2015 ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. DRG, MAP, mRNA
55  2015 ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. AD, FTDs, PSP, SWI/SNF
56  2015 Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoactive intestinal peptide (VIP) concentrations in treatment-naive humans with multiple sclerosis. BDNF, CNS, MS, VIP
57  2015 Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. AD, MCI
58  2015 In vivo and in vitro ketamine exposure exhibits a dose-dependent induction of activity-dependent neuroprotective protein in rat neurons. 3 DIV
59  2015 Novel hexapeptide interacts with tubulin and microtubules, inhibits Abeta fibrillation, and shows significant neuroprotection. NGF
60  2015 Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. DISC1, EB, Foxp2
61  2015 The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. EB, LC3
62  2014 Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. AD
63  2014 Davunetide: Peptide therapeutic in neurological disorders. ---
64  2014 NAP alpha-aminoisobutyric acid (IsoNAP). AD
65  2014 Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. BRM, FTDs, PTB, SWI/SNF
66  2014 The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. MT, PSD-95
67  2013 Autophagy has a key role in the pathophysiology of schizophrenia. LC3
68  2013 Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). ---
69  2012 D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. ALS
70  2012 Ethanol disrupts axon outgrowth stimulated by netrin-1, GDNF, and L1 by blocking their convergent activation of Src family kinase signaling. BDNF, CGN, FASD, GDNF, SFK
71  2012 Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells. MPNST, MPNSTs, NS, PACAP, SS
72  2012 Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). ---
73  2012 Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. DMSO, MEL
74  2012 Strategies to defeat ketamine-induced neonatal brain injury. AC3, NAP
75  2012 The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. MTs
76  2011 Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. ---
77  2011 Activity-dependent neuroprotective protein modulates its own gene expression. ---
78  2011 Ameliorative effect of NAP on laser-induced retinal damage. ---
79  2011 HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeats. PTM
80  2011 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). MAP2, PSP
81  2011 NAP (davunetide) provides functional and structural neuroprotection. ---
82  2011 Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. ADNF, SAL
83  2010 Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. ---
84  2010 Expression of peptide NAP in rat retinal Muller cells prevents hypoxia-induced retinal injuries and promotes retinal neurons growth. NT4, RMC
85  2010 Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. STOP
86  2010 NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. STOP
87  2010 Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. ---
88  2010 Tau pathology and future therapeutics. AD, CBD, FTD, PSP
89  2010 The effects of nitric oxide inhibition prior to kainic acid treatment on neuro- and gliogenesis in the rat dentate gyrus in vivo and in vitro. KA, NOS, SGZ
90  2010 VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina. BDNF, NMDA, PACAP-38, VIP
91  2009 Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. AD, VIP, WT
92  2009 NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). ADNF-9
93  2009 NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. NAP
94  2009 Nitric oxide regulates activity-dependent neuroprotective protein (ADNP) in the dentate gyrus of the rodent model of kainic acid-induced seizure. 7-NI, DG, KA, NO
95  2008 ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. ---
96  2008 Ethanol inhibits neuronal differentiation by disrupting activity-dependent neuroprotective protein signaling. Cas, CNS, NAP
97  2008 NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. ---
98  2008 Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss. ADNF, NAP, SAL
99  2008 Regulation of activity-dependent neuroprotective protein (ADNP) by the NO-cGMP pathway in the hippocampus during kainic acid-induced seizure. iNOS, KA, nNOS, sGC
100  2008 Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. ---